Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 291

1.

Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy.

Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Shariat SF.

Urol Oncol. 2020 Feb 29. pii: S1078-1439(20)30049-1. doi: 10.1016/j.urolonc.2020.02.008. [Epub ahead of print]

PMID:
32127252
2.

Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration.

Soria F, Giordano A, D'Andrea D, Moschini M, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Bensalah K, Mathieu R, Chlosta P, Babjuk M, Glybochko PV, Enikeev DV, Remzi M, Gust K, Gontero P, Shariat SF.

Urol Oncol. 2020 Feb 6. pii: S1078-1439(20)30005-3. doi: 10.1016/j.urolonc.2020.01.004. [Epub ahead of print]

PMID:
32037197
3.

Reply by Authors.

Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; and Collaborators; and Collaborators.

J Urol. 2020 Jan 22:101097JU000000000000064402. doi: 10.1097/JU.0000000000000644.02. [Epub ahead of print] No abstract available.

PMID:
31967495
4.

Efficacy of Preoperative Chemotherapy in High Risk Upper Tract Urothelial Carcinoma.

Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF.

J Urol. 2020 Jan 2:101097JU0000000000000737. doi: 10.1097/JU.0000000000000737. [Epub ahead of print]

PMID:
31898919
5.

PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.

Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ.

Urol Oncol. 2019 Dec 17. pii: S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. [Epub ahead of print]

PMID:
31862213
6.

Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.

Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, Cadeddu J, Margulis V, Pedrosa I, Rakheja D, McKay RM, Brugarolas J, Kapur P.

EBioMedicine. 2020 Jan;51:102526. doi: 10.1016/j.ebiom.2019.10.052. Epub 2019 Dec 16.

7.

Advancements in the clinical management of upper tract urothelial carcinoma.

Taylor J, Meng X, Ghandour R, Margulis V.

Expert Rev Anticancer Ther. 2019 Dec;19(12):1051-1060. doi: 10.1080/14737140.2019.1698295. Epub 2019 Dec 6. Review.

PMID:
31770492
8.

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.

Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; and Collaborators; and Collaborators.

J Urol. 2019 Nov 8:101097JU0000000000000644. doi: 10.1097/JU.0000000000000644. [Epub ahead of print]

PMID:
31702432
9.

Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection.

Lafin JT, Singla N, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A.

Eur Urol. 2020 Feb;77(2):290-292. doi: 10.1016/j.eururo.2019.10.005. Epub 2019 Nov 5. No abstract available.

PMID:
31699528
10.

Tumor location does not limit percutaneous treatment of small renal masses with microwave ablation.

Meng X, Ghandour R, Margulis V.

Ann Transl Med. 2019 Sep;7(Suppl 6):S231. doi: 10.21037/atm.2019.08.70. No abstract available.

11.

Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.

Singla N, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rapoport L, Enikeev M, Lohrey J, Woldu SL, Gahan JC, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V.

Urol Oncol. 2019 Dec;37(12):924-931. doi: 10.1016/j.urolonc.2019.08.012. Epub 2019 Sep 12.

PMID:
31522865
12.

Current advances in BCG-unresponsive non-muscle invasive bladder cancer.

Tse J, Singla N, Ghandour R, Lotan Y, Margulis V.

Expert Opin Investig Drugs. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15. Review.

PMID:
31412742
13.

Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy.

Freifeld Y, Woldu SL, Singla N, Clinton T, Bagrodia A, Hutchinson R, Lotan Y, Margulis V.

Eur Urol Oncol. 2019 Nov;2(6):691-698. doi: 10.1016/j.euo.2018.10.005. Epub 2018 Nov 16.

PMID:
31411983
14.

Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma.

Freifeld Y, Ghandour R, Singla N, Woldu S, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, Lotan Y, Margulis V.

Urol Oncol. 2019 Oct;37(10):758-764. doi: 10.1016/j.urolonc.2019.06.009. Epub 2019 Aug 2.

PMID:
31378586
15.

Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.

Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):367-375. doi: 10.1016/j.ijrobp.2019.07.023. Epub 2019 Aug 1.

PMID:
31377159
16.

Is cytoreductive nephrectomy relevant in the immunotherapy era?

Singla N, Ghandour RA, Margulis V.

Curr Opin Urol. 2019 Sep;29(5):526-530. doi: 10.1097/MOU.0000000000000659.

PMID:
31305273
17.

Cytoreductive nephrectomy: future directions.

Margulis V, Hakimi AA.

Curr Opin Urol. 2019 Sep;29(5):540-541. doi: 10.1097/MOU.0000000000000662. No abstract available.

PMID:
31305272
18.

Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.

Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA.

Eur Urol Oncol. 2019 Jul;2(4):397-404. doi: 10.1016/j.euo.2018.08.022. Epub 2018 Sep 20.

PMID:
31277776
19.

Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.

Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia A.

Eur Urol Oncol. 2019 Jul 1. pii: S2588-9311(19)30082-3. doi: 10.1016/j.euo.2019.06.007. [Epub ahead of print]

PMID:
31272940
20.

Editorial: The evolving role of cytoreductive nephrectomy.

Singla N, Hakimi AA, Margulis V.

Curr Opin Urol. 2019 Sep;29(5):505-506. doi: 10.1097/MOU.0000000000000653. No abstract available.

PMID:
31246591
21.

EDITORIAL COMMENT.

Singla N, Margulis V.

Urology. 2019 Jul;129:85. doi: 10.1016/j.urology.2019.01.062. No abstract available.

PMID:
31235006
22.

Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis.

Satyanarayan A, Mooney R, Bhanvadia RR, Iyengar P, Margulis V, Desai NB, Bagrodia A.

Clin Genitourin Cancer. 2019 Aug;17(4):e768-e771. doi: 10.1016/j.clgc.2019.04.005. Epub 2019 Apr 26. No abstract available.

PMID:
31109801
23.

Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract.

Aragon-Ching JB, Choudhury A, Margulis V, Yu EY.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:262-275. doi: 10.1200/EDBK_237451. Epub 2019 May 17. Review.

24.

Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A.

Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6.

25.

The use of cytoreductive nephrectomy in patients with renal cell carcinoma.

Ghandour RA, Singla N, Margulis V.

Expert Rev Anticancer Ther. 2019 May;19(5):405-411. doi: 10.1080/14737140.2019.1606716. Epub 2019 Apr 25. Review.

PMID:
31020871
26.

Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy.

Lotan Y, Margulis V.

Lancet Oncol. 2019 Apr;20(4):473-475. doi: 10.1016/S1470-2045(19)30024-5. Epub 2019 Mar 14. No abstract available.

PMID:
30880069
27.

Editorial Comment.

Singla N, Margulis V.

J Urol. 2019 Jun;201(6):1086. doi: 10.1097/01.JU.0000554454.85780.7a. No abstract available.

PMID:
30835609
28.

Sex differences in upper tract urothelial carcinomas.

Singla N, Ghandour RA, Margulis V.

Curr Opin Urol. 2019 May;29(3):256-260. doi: 10.1097/MOU.0000000000000596. Review.

PMID:
30762671
29.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13.

PMID:
30759271
30.

Transesophageal Echocardiography Imaging of the Inferior Vena Cava and Hepatic Vein Masses.

Blinn JA, Margulis V, Joshi RV.

A A Pract. 2019 Apr 15;12(8):295-297. doi: 10.1213/XAA.0000000000000951. No abstract available.

PMID:
30633001
31.

Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma.

Petros FG, Qiao W, Singla N, Clinton TN, Robyak H, Raman JD, Margulis V, Matin SF.

Urol Oncol. 2019 Apr;37(4):292.e1-292.e9. doi: 10.1016/j.urolonc.2018.12.002. Epub 2018 Dec 22.

PMID:
30584035
32.

Editorial Comment.

Singla N, Hannan R, Margulis V.

J Urol. 2019 Jan;201(1):76. doi: 10.1097/01.ju.0000550124.15721.0f. No abstract available. Erratum in: J Urol. 2019 Apr;201(4):821.

PMID:
30577392
33.

Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer.

Bhanvadia RR, Woldu SL, Margulis V, Subramaniam RM, Bagrodia A.

Clin Genitourin Cancer. 2019 Feb;17(1):e184-e186. doi: 10.1016/j.clgc.2018.10.014. Epub 2018 Oct 29. No abstract available.

PMID:
30454969
34.

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN.

Urol Oncol. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. Epub 2018 Nov 13.

PMID:
30446460
35.

Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Rieken M, Boorjian SA, Kluth LA, Capitanio U, Briganti A, Thompson RH, Leibovich BC, Krabbe LM, Margulis V, Raman JD, Regelman M, Karakiewicz PI, Rouprêt M, Abufaraj M, Foerster B, Gönen M, Shariat SF.

World J Urol. 2019 Aug;37(8):1631-1637. doi: 10.1007/s00345-018-2555-5. Epub 2018 Nov 7.

36.

Need for upper urinary tract stenting in cases of ureteral orifice injury during laser enucleation of the prostate.

Enikeev D, Glybochko P, Rapoport L, Snurnitsyna O, Potoldykova N, Novoselova T, Laukhtina E, Taratkin M, Margulis V.

Int Urol Nephrol. 2018 Dec;50(12):2173-2177. doi: 10.1007/s11255-018-2007-6. Epub 2018 Oct 22.

PMID:
30349963
37.

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.

Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V.

Clin Genitourin Cancer. 2018 Dec;16(6):e1221-e1235. doi: 10.1016/j.clgc.2018.08.001. Epub 2018 Aug 25.

PMID:
30217763
38.

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE.

Eur Urol Focus. 2020 Jan 15;6(1):104-111. doi: 10.1016/j.euf.2018.08.023. Epub 2018 Sep 8.

PMID:
30206003
39.

Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.

Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA.

Cell Metab. 2018 Nov 6;28(5):793-800.e2. doi: 10.1016/j.cmet.2018.07.020. Epub 2018 Aug 23.

40.

Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma.

Freifeld Y, Ananthakrishnan L, Margulis V.

Curr Urol Rep. 2018 Aug 16;19(10):82. doi: 10.1007/s11934-018-0829-5. Review.

PMID:
30116909
41.

Molecularly-driven precision medicine for advanced bladder cancer.

Krabbe LM, Margulis V, Schrader AJ, Shariat SF, Gust KM, Boegemann M.

World J Urol. 2018 Nov;36(11):1749-1757. doi: 10.1007/s00345-018-2354-z. Epub 2018 Jun 8. Review.

PMID:
29948043
42.

Therapeutic strategies for upper tract urothelial carcinoma.

Freifeld Y, Krabbe LM, Clinton TN, Woldu SL, Margulis V.

Expert Rev Anticancer Ther. 2018 Aug;18(8):765-774. doi: 10.1080/14737140.2018.1481395. Epub 2018 Jun 8. Review.

PMID:
29848133
43.

What is the role of nephrectomy following complete response to checkpoint inhibitors?

Woldu SL, Brugarolas J, Kapur P, Margulis V.

Urol Case Rep. 2018 Mar 14;18:60-63. doi: 10.1016/j.eucr.2018.02.016. eCollection 2018 May. No abstract available.

44.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
45.

Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence.

Rieken M, Kluth LA, Fajkovic H, Capitanio U, Briganti A, Krabbe LM, Margulis V, Abufaraj M, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, Shariat SF.

Clin Genitourin Cancer. 2018 Aug;16(4):e903-e908. doi: 10.1016/j.clgc.2018.03.003. Epub 2018 Mar 24.

PMID:
29653814
46.

Multi-institutional Evaluation of Upper Urinary Tract Biopsy Using Backloaded Cup Biopsy Forceps, a Nitinol Basket, and Standard Cup Biopsy Forceps.

Lama DJ, Safiullah S, Patel RM, Lee TK, Balani JP, Zhang L, Okhunov Z, Margulis V, Savage SJ, Uchio E, Landman J.

Urology. 2018 Jul;117:89-94. doi: 10.1016/j.urology.2018.03.040. Epub 2018 Apr 6.

47.

The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus.

Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V.

Urology. 2018 May;115:119-124. doi: 10.1016/j.urology.2018.02.019. Epub 2018 Feb 27.

PMID:
29499258
48.

Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma.

Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB.

J Urol. 2018 Jun;199(6):1440-1445. doi: 10.1016/j.juro.2018.02.002. Epub 2018 Feb 7.

PMID:
29427584
49.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Apr;36(4):159.e7-159.e17. doi: 10.1016/j.urolonc.2017.12.001. Epub 2017 Dec 26.

PMID:
29288008
50.

Tissue-based biomarkers in prostate cancer.

Clinton TN, Bagrodia A, Lotan Y, Margulis V, Raj GV, Woldu SL.

Expert Rev Precis Med Drug Dev. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5.

Supplemental Content

Loading ...
Support Center